Abstract: There is provided a lipid mix composition comprising ionizable lipid, a structural lipid such as DSPC, a sterol, and a surfactant such as polysorbate 80, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, or D-?-Tocopherol polyethylene glycol 1000 succinate. The lipid mix compositions find particular use in transfecting difficult to transfect cells and maintaining the viability of those cells. The lipid mix compositions are particularly well suited to T cell transfection ex vivo.

Abstract: A “smart ” instrument for mixing (100), a microfluidic chip (50), and a system wherein they are used to prepare formulations is provided. The microfluidic chip comprises microchannels and a programmable data component. The system achieves optimal formulations for RNA, antisense, peptides and small molecules in the hands of even novice users.

Abstract: A transfection reagent composition comprising: 30-60 MOL % of an cationic lipid, or pharmaceutical acceptable salt thereof; 10-60 MOL % structural lipid; a sterol and 0.1 to about 10 MOL % of a stabilizing agent is provided. The reagent is particularly adapted for neuron and related cell types. A method of manufacturing LNP including nucleic acid for selective uptake into either neurons or astrocytes or neural progenitor cells is also provided.

Abstract: A “smart” instrument for mixing (100), a microfluidic chip (50), and a system wherein they are used to prepare formulations is provided. The microfluidic chip comprises microchannels and a programmable data component. The system achieves optimal formulations for RNA, antisense, peptides and small molecules in the hands of even novice users.

Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.

Abstract: The present invention provides a microfluidic mixing platform having a bulk, the platform including an inlet well, a microchannel, a passive capillary valve a mixing feature and an outlet. The passive capillary valve prevents unwanted capillary flow along the microchannel. The passive capillary valve comprises a widening of the microchannel relative to the direction of fluid flow, and the angle has a graduated profile. The mixing platform bulk comprises a rigid matrix capable of machine manufacture. A method of preventing backflow in a microfluidic mixer is also provided.

Abstract: A “smart” instrument for mixing (100), a microfluidic chip (50), and a system wherein they are used to prepare formulations is provided. The microfluidic chip comprises microchannels and a programmable data component. The system achieves optimal formulations for RNA, antisense, peptides and small molecules in the hands of even novice users.

Abstract: A transfection reagent composition comprising: 30-60 MOL. % of a cationic lipid, or a pharmaceutical acceptable salt thereof; 10-60 MOL % of a structural lipid; 10-20 MOL % of a triglyceride; and 0.1 to about 10 MOL. % of a stabilizing agent, is provided. The transfection agent is effective in transfecting cells, particularly neurons, with siRNA, mRNA and plasmid nucleic acid, Sand maintaining viability of the cells as well as activity of the delivered nucleic acid.